Vertex HIV Drug Candidate Development Halted by GlaxoSmithKline Because of Formulation Problem
December 22, 2006
GlaxoSmithKline has stopped collaborating with Vertex Pharmaceuticals Inc. on the HIV drug candidate brecanavir (VX-385), Vertex said in a recent Securities and Exchange Commission filing. The drug, which was in mid-stage clinical testing, would be too difficult to formulate, said Glaxo. The firms have collaborated since 1993, yielding the HIV treatments Agenerase and Lexiva.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.